Hamburg - The law firm NEUWERK advised Polpharma Biologics on the conclusion of a cooperation and license agreement for the joint development and marketing of the biosimilar Natalizumab with Novartis generics subsidiary Sandoz.
The drug is currently in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS). Under the terms of the agreement, Polpharma will be responsible for the development, manufacture and supply of the biosimilar. Sandoz will commercialize and distribute the drug in all markets upon approval, through an exclusive global license. Other specific terms of the agreement are confidential.
Polpharma Biologics is a European biopharmaceutical company focused on the development and manufacture of biosimilars and novel biological drugs. With the agreement, the parties intend to combine their expertise to provide more patients with access to novel RRMS treatment options.
Börge Seeger, licensing specialist and partner at NEUWERK in Hamburg: ''This is our first project with Polpharma Biologics, and we are pleased to have accompanied the company in such an important licensing deal".
Advisors for Polpharma: NEUWERK, Hamburg Börge Seeger, MLE, JSM, CLP (transaction lead, partner) Dr. Jonas Welge (Associate)
About NEUWERK: NEUWERK was founded in 2016 by lawyers from Freshfields Bruckhaus Deringer and ROXIN in Hamburg. NEUWERK brings together specialists from the fields of labor law, corporate law/M&A, IP/IT, real estate law, litigation and white-collar criminal law/criminal compliance.
Press contact: For further questions please contact Dr. Sebastian Naber (firstname.lastname@example.org), T +49 40 340 5757-30.
NEUWERK Rechtsanwälte PartG mbB, Gänsemarkt 35, 20354 Hamburg, Germany www.neuwerk.legal